Volume 24, Number 12—December 2018
CME ACTIVITY - Research
Substance Use and Adherence to HIV Preexposure Prophylaxis for Men Who Have Sex with Men1
Martin Hoenigl
, Sonia Jain, David Moore, Deborah Collins, Xiaoying Sun, Peter L. Anderson, Katya Corado, Jill S. Blumenthal, Eric S. Daar, Joel Milam, Michael P. Dubé, Sheldon Morris, and for the California Collaborative Treatment Group 595 Team
, Sonia Jain, David Moore, Deborah Collins, Xiaoying Sun, Peter L. Anderson, Katya Corado, Jill S. Blumenthal, Eric S. Daar, Joel Milam, Michael P. Dubé, Sheldon Morris, and for the California Collaborative Treatment Group 595 Team
Table 3
Associations of substance/alcohol use at baseline with study completion and incident STI among MSM and transgender women, California, USA*
| Substance use baseline, n = 394 |
Study completion |
p value |
Incident STI |
p value |
||
|---|---|---|---|---|---|---|
| No |
Yes |
No |
Yes |
|||
| DAST10 problems | 0.59 | 0.043 | ||||
| No/low | 42 (17) | 207 (83) | 161 (65) | 88 (35) | ||
| Moderate | 25 (21) | 95 (79) | 63 (53) | 57 (48) | ||
| Substantial/severe | 5 (20) | 20 (80) | 18 (72) | 7 (28) | ||
| Methamphetamine | 0.15 | 0.037 | ||||
| No | 56 (17) | 275 (83) | 211 (64) | 120 (36) | ||
| Some | 12 (30) | 28 (70) | 17 (43) | 23 (57) | ||
| Frequent | 4 (17) | 19 (83) | 14 (61) | 9 (39) | ||
| Heroin | 0.24 | 0.80 | ||||
| No | 67 (18) | 310 (82) | 230 (61) | 115 (39) | ||
| Some | 2 (22) | 7 (78) | 6 (67) | 1 (33) | ||
| Frequent | 3 (38) | 5 (63) | 6 (75) | 2 (25) | ||
| Poppers | 0.25 | <0.001 | ||||
| No | 41 (21) | 150 (79) | 142 (74) | 49 (26) | ||
| Some | 19 (17) | 94 (83) | 57 (50) | 56 (50) | ||
| Frequent | 12 (13) | 78 (87) | 43 (48) | 47 (52) | ||
| Cocaine | 0.31 | 0.18 | ||||
| No | 58 (17) | 276 (83) | 211 (63) | 123 (37) | ||
| Some | 9 (20) | 35 (80) | 24 (55) | 20 (45) | ||
| Frequent | 5 (31) | 11 (69) | 7 (44) | 9 (56) | ||
| Stimulant substances† | 0.40 | <0.001 | ||||
| No | 30 (22) | 109 (78) | 110 (79) | 29 (21) | ||
| Some | 23 (18) | 106 (82) | 67 (52) | 62 (48) | ||
| Frequent | 19 (15) | 107 (85) | 65 (52) | 61 (48) | ||
| Nonstimulant substances‡ | 0.95 | 0.33 | ||||
| No | 42 (19) | 179 (81) | 140 (63) | 81 (37) | ||
| Some | 19 (18) | 89 (82) | 60 (56) | 48 (44) | ||
| Frequent | 11 (17) | 54 (83) | 42 (65) | 23 (35) | ||
| Any substance | 0.18 | <0.001 | ||||
| No | 25 (24) | 81 (76) | 81 (76) | 25 (24) | ||
| Some | 25 (19) | 110 (81) | 76 (56) | 59 (44) | ||
| Frequent | 22 (14) | 131 (86) | 85 (56) | 68 (44) | ||
| Alcohol | 0.13 | 0.28 | ||||
| No | 16 (24) | 51 (76) | 47 (70) | 20 (30) | ||
| Some | 21 (22) | 74 (78) | 57 (60) | 38 (40) | ||
| Frequent | 35 (15) | 197 (85) | 138 (59) | 94 (41) | ||
*Values are no. (%). DAST, Drug Abuse Screening Test; DBS, dried blood spot; MSM, men who have sex with men; STI, sexually transmitted infection.
†Includes poppers, methamphetamine, cocaine, ecstasy, amphetamine, and other stimulants.
‡Marijuana and alcohol excluded.
1Original data from this study were presented in part at the 2017 Conference on Retroviruses and Opportunistic Infections, February 13–16, 2017, Seattle, Washington, USA; and at the 12th International Conference on HIV Treatment and Prevention Adherence, June 4–6, 2017, Miami, Florida, USA.
Page created: November 14, 2018
Page updated: November 14, 2018
Page reviewed: November 14, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.